Month: November 2021

Looking forward to presenting on #suprachoroidal delivery at the Ophthalmology I…

[ad_1] Looking forward to presenting on #suprachoroidal delivery at the Ophthalmology Innovation Source Drug Delivery Innovation Showcase! #eye #retina #drugdelivery #genetherapy #biotech https://t.co/QC85uDRp2f [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

Just published, “RPE65 Mutation-associated Inherited Retinal Disease and Gene Th…

[ad_1] Just published, “RPE65 Mutation-associated Inherited Retinal Disease and Gene Therapies”. #eye #ophthalmology #retina #gene #IRD #genetherapy #clinicalresearch #clinicaltrials #drugdevelopment #biotech https://t.co/4zpccyQV2P [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @OTEurope: XIPERE, the first therapy utilising the suprachoroidal space, demo…

[ad_1]
RT @OTEurope: XIPERE, the first therapy utilising the suprachoroidal space, demonstrates rapid efficacy, durable benefit and favourable saf…
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @ThomasCiullaMD: Honored to have been interviewed by @retinapodcast on resear…

[ad_1] RT @ThomasCiullaMD: Honored to have been interviewed by @retinapodcast on research, roles in industry, and innovations in retinal therapeut… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

Suprachoroidal RGX-314 well tolerated, improves visual acuity in initial results…

[ad_1] Suprachoroidal RGX-314 well tolerated, improves visual acuity in initial results https://t.co/HZmaJEVIAc [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @AuraBiosciences: Aura is proud to share that Dr. Hakan Demirci’s scientific …

[ad_1]
RT @AuraBiosciences: Aura is proud to share that Dr. Hakan Demirci’s scientific poster updating the safety data of the Phase 2 AU-011 trial…
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

Congrats to colleagues, partners & team, with numerous #aao2021 & AUS presentati…

[ad_1] Congrats to colleagues, partners & team, with numerous #aao2021 & AUS presentations on #suprachoroidal delivery, utilizing the SCS Microinjector. Beyond recently FDA-approved #Xipere, 4 clinical trials are now assessing 3 suprachoroidal therapies. #eye #retina #genetherapy https://t.co/25TR3ccT06 [ad_2] Source by Thomas Ciulla, MD, MBA Return 

RT @RetinalPhys: Data Presented From 2 Regenxbio Trials: ALTITUDE and AAVIATE tr…

[ad_1] RT @RetinalPhys: Data Presented From 2 Regenxbio Trials: ALTITUDE and AAVIATE trials promising for subretinal and suprachoroidal delivery o… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @surgeonretina: Nice to see my former @MassEyeAndEar co-resident and now at @…

[ad_1]
RT @surgeonretina: Nice to see my former @MassEyeAndEar co-resident and now at @UCDavisMedCntr @ucdavisvetmed Dr Glenn Yiu presenting on th…
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

VIDEO: Suprachoroidal delivery ‘brings gene therapy into the office setting’ for…

[ad_1] VIDEO: Suprachoroidal delivery ‘brings gene therapy into the office setting’ for wet AMD https://t.co/iK20ZtGrmq [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.